CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
The FDA has authorized the Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu, allowing patients with advanced solid tumors access to ...
CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ...
FDA authorization and Institutional Review Board (IRB) approval followed by QP release for expanded access treatment of one patient in the US Treatment scheduled in November 2025 at the University of ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On June 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it attained Expanded Access ...
“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results